Compound comparison
Sermorelin and tesamorelin are both synthetic analogs of growth hormone-releasing hormone (GHRH) that stimulate endogenous GH secretion via pituitary GHRH receptors. Despite their mechanistic similarity, their regulatory trajectories diverge sharply. Tesamorelin (Egrifta) is FDA-approved for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy, backed by a Phase 3 trial published in the New England Journal of Medicine (Falutz et al., 2010). Sermorelin (Geref) was previously FDA-approved as a diagnostic agent for pediatric growth hormone deficiency but was discontinued by the manufacturer and is no longer commercially available under an FDA-approved brand; it is now compounded by telehealth clinics for off-label adult use. This comparison documents their overlapping mechanism, divergent evidence bases, and distinct regulatory and availability landscapes.
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Mechanism | Synthetic 1-29 fragment of GHRH; stimulates endogenous GH release via pituitary GHRH receptors, mirroring the natural GHRH signal | Stabilized synthetic GHRH analog; stimulates endogenous GH release via pituitary GHRH receptors, increasing lipolysis and reducing visceral fat accumulation |
| FDA approval status | Previously FDA-approved as Geref for diagnostic use in pediatric GH deficiency; brand product discontinued by manufacturer (not a safety withdrawal) | Currently FDA-approved as Egrifta (2010) for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy |
| Evidence level | Published clinical literature primarily from 1990s–2000s era focusing on pediatric GH deficiency diagnostic testing; modern adult off-label use lacks robust clinical trial data | Phase 3 randomized trial published in NEJM (Falutz et al., 2010) showing significant VAT reduction in HIV lipodystrophy patients; FDA drug label available |
| Approved indication | Former: diagnostic testing for growth hormone deficiency in children (discontinued) | Current: reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy |
| Regulatory status | No currently marketed FDA-approved brand product; compounded for off-label adult use under FDA bulk substance risk-list framework; subject to FDA enforcement on compounding and telehealth marketing | FDA-approved branded product (Egrifta) with an active drug label; off-label use in non-HIV populations is outside the approved indication and subject to FDA enforcement when marketed inappropriately |
| Availability | No FDA-approved brand product available; widely compounded by telehealth and anti-aging clinics for off-label adult use; also sold by research-use-only vendors | Available as FDA-approved branded product (Egrifta) via prescription; also discussed in online communities for off-label use outside the approved HIV lipodystrophy indication |
| Off-label use patterns | Telehealth compounding for adult anti-aging and performance use; lacks clinical trial evidence for these applications | Community discussion of off-label fat loss in non-HIV populations; no FDA approval for general obesity or cosmetic fat loss |
Sermorelin is a synthetic 29-amino-acid N-terminal fragment of growth hormone-releasing hormone (GHRH) that was formerly FDA-approved as the brand product Geref for diagnostic use in evaluating pediatric growth hormone deficiency. It stimulates endogenous GH release by binding pituitary GHRH receptors, mirroring the natural GHRH signal.
The manufacturer (EMD Serono) discontinued Geref; the FDA-approved brand product is no longer commercially available. The discontinuation was a business decision, not an FDA safety withdrawal. Published clinical literature for sermorelin is primarily from the 1990s–2000s era and focuses on pediatric GH deficiency diagnostic testing.
Sermorelin is now widely compounded by telehealth and anti-aging clinics for off-label adult use. This compounding falls under FDA oversight and the bulk drug substances risk-list framework. Modern adult off-label use lacks the clinical trial evidence base that supported the original pediatric diagnostic approval.
Tesamorelin (brand name Egrifta) is a stabilized synthetic GHRH analog that received FDA approval in 2010 for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It is the only GHRH/GHS-class peptide with current FDA approval.
The pivotal Phase 3 trial was published in the New England Journal of Medicine (Falutz et al., 2010; PMID 20879920), demonstrating significant reduction in visceral adipose tissue (VAT) over 26 weeks in HIV patients with lipodystrophy. The FDA drug label is available on accessdata.fda.gov.
Like sermorelin, tesamorelin stimulates endogenous GH release via pituitary GHRH receptors. Its approved indication is specific to HIV-associated lipodystrophy — not general obesity or cosmetic fat loss. Online communities discuss tesamorelin for off-label fat loss in non-HIV populations, which is outside the FDA-approved indication.
Sermorelin and tesamorelin share a fundamental mechanism — both are GHRH analogs that stimulate endogenous GH release via pituitary GHRH receptors. Their regulatory and evidence trajectories diverge sharply: tesamorelin (Egrifta) is currently FDA-approved for HIV-associated lipodystrophy with Phase 3 trial support published in NEJM, while sermorelin (Geref) was previously FDA-approved for pediatric GH deficiency diagnostic testing but is no longer commercially available as a brand product and is now compounded for off-label adult use without robust modern clinical evidence. This comparison documents mechanistic overlap and divergent regulatory status; it does not recommend either compound or provide treatment guidance.
Related compounds: Sermorelin · Tesamorelin · CJC-1295
Source records are stored in the repo and linked from this comparison.
FDA-approved drug label for Egrifta (tesamorelin for injection), indicated for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. The only GHRH/GHS-class peptide with FDA approval.
Pivotal Phase 3 randomized trial (Falutz et al., 2010; PMID 20879920) showing tesamorelin significantly reduced visceral adipose tissue (VAT) over 26 weeks in HIV-infected patients with lipodystrophy. This trial supported FDA approval of Egrifta.
ClinicalTrials.gov registry entries for tesamorelin clinical trials, including the pivotal Phase 3 trials for HIV-associated lipodystrophy that supported FDA approval of Egrifta.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
PubMed index of clinical literature on sermorelin (Geref) for diagnostic testing of growth hormone deficiency in pediatric patients. Sermorelin was formerly FDA-approved as Geref; the brand product has been discontinued by the manufacturer.